Wells Fargo & Company Intercept Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.99 - $18.71 $729,719 - $1.37 Million	-73,045 Reduced 50.22%	72,409 $1.34 Million
Q2 2023 Aug 15, 2023	BUY	$9.17 - $19.29 $257,823 - $542,357	28,116 Added 23.96%	145,454 $1.61 Million
Q1 2023 May 12, 2023	BUY	$12.53 - $21.71 $605,762 - $1.05 Million	48,345 Added 70.07%	117,338 $1.58 Million
Q4 2022 Feb 13, 2023	SELL	$11.61 - $16.11 $278,628 - $386,623	-23,999 Reduced 25.81%	68,993 $853,000
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $258,497 - $417,068	21,171 Added 29.48%	92,992 $1.3 Million
Q2 2022 Aug 12, 2022	SELL	$11.23 - $19.59 $195,031 - $340,219	-17,367 Reduced 19.47%	71,821 $991,000
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $34,655 - $46,111	-2,592 Reduced 2.82%	89,188 $1.45 Million
Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $934,368 - $1.28 Million	-65,432 Reduced 41.62%	91,780 $1.49 Million
Q3 2021 Nov 15, 2021	BUY	$12.99 - $20.47 $1.1 Million - $1.74 Million	84,832 Added 117.2%	157,212 $2.33 Million
Q2 2021 Aug 16, 2021	BUY	$15.46 - $24.5 $520,028 - $824,106	33,637 Added 86.82%	72,380 $1.45 Million
Q1 2021 May 13, 2021	SELL	$19.33 - $37.75 $649,043 - $1.27 Million	-33,577 Reduced 46.43%	38,743 $895,000
Q4 2020 Feb 09, 2021	BUY	$24.48 - $42.47 $618,022 - $1.07 Million	25,246 Added 53.63%	72,320 $1.79 Million
Q3 2020 Nov 05, 2020	SELL	$39.09 - $53.44 $1.19 Million - $1.62 Million	-30,334 Reduced 39.19%	47,074 $1.95 Million
Q2 2020 Aug 13, 2020	SELL	$46.7 - $92.04 $133,095 - $262,314	-2,850 Reduced 3.55%	77,408 $3.71 Million
Q1 2020 May 14, 2020	BUY	$48.35 - $118.68 $3.88 Million - $9.53 Million	80,258 New	80,258 $5.05 Million

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account